Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key
Executive Summary
Eli Lilly's Olumiant (baricitinib) has won a green light from the European Medicines Agency's CHMP, for treating rheumatoid arthritis. It has advantages over future rival and fellow JAK inhibitor Xeljanz, but pricing will be key for competing against more established treatments.
You may also be interested in...
Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.
Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too
Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.